226 related articles for article (PubMed ID: 23350812)
21. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
Dewey RB; Hutton JT; LeWitt PA; Factor SA
Arch Neurol; 2001 Sep; 58(9):1385-92. PubMed ID: 11559309
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
[TBL] [Abstract][Full Text] [Related]
23. Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients.
Thijssen E; den Heijer JM; Puibert D; van Brummelen EMJ; Naranda T; Groeneveld GJ
Parkinsonism Relat Disord; 2022 Apr; 97():84-90. PubMed ID: 35366574
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
[TBL] [Abstract][Full Text] [Related]
25. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
Thijssen E; den Heijer J; Puibert D; Moss L; Lei M; Hasegawa D; Keum K; Mochel K; Ezzeldin Sharaf M; Alfredson T; Zeng W; van Brummelen E; Naranda T; Groeneveld GJ
Mov Disord; 2022 Apr; 37(4):790-798. PubMed ID: 35048423
[TBL] [Abstract][Full Text] [Related]
27. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
Caughman CY; Factor S
Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
[No Abstract] [Full Text] [Related]
28. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
De Cock VC; Dodet P; Leu-Semenescu S; Aerts C; Castelnovo G; Abril B; Drapier S; Olivet H; Corbillé AG; Leclair-Visonneau L; Sallansonnet-Froment M; Lebouteux M; Anheim M; Ruppert E; Vitello N; Eusebio A; Lambert I; Marques A; Fantini ML; Devos D; Monaca C; Benard-Serre N; Lacombe S; Vidailhet M; Arnulf I; Doulazmi M; Roze E
Lancet Neurol; 2022 May; 21(5):428-437. PubMed ID: 35429481
[TBL] [Abstract][Full Text] [Related]
29. A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.
Gurrell R; Duvvuri S; Sun P; DeMartinis N
Clin Drug Investig; 2018 Jun; 38(6):509-517. PubMed ID: 29478239
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
32. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
[TBL] [Abstract][Full Text] [Related]
33. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
Dula E; Bukofzer S; Perdok R; George M;
Eur Urol; 2001 May; 39(5):558-3; discussion 564. PubMed ID: 11464037
[TBL] [Abstract][Full Text] [Related]
34. Apomorphine (Apokyn) for advanced Parkinson's Disease.
Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705
[TBL] [Abstract][Full Text] [Related]
35. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
36. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
Gunzler SA; Koudelka C; Carlson NE; Pavel M; Nutt JG
Arch Neurol; 2008 Feb; 65(2):193-8. PubMed ID: 18268187
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group.
Dula E; Keating W; Siami PF; Edmonds A; O'neil J; Buttler S
Urology; 2000 Jul; 56(1):130-5. PubMed ID: 10869641
[TBL] [Abstract][Full Text] [Related]
38. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
Hauser RA; Isaacson S; Clinch T;
Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
[TBL] [Abstract][Full Text] [Related]
39. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations.
Manson AJ; Hanagasi H; Turner K; Patsalos PN; Carey P; Ratnaraj N; Lees AJ
Brain; 2001 Feb; 124(Pt 2):331-40. PubMed ID: 11157560
[TBL] [Abstract][Full Text] [Related]
40. Apomorphine for Parkinson's disease: pharmacologic and clinical considerations.
Wagner MJ; Daniel CP; Plaisance CJ; Borne GE; Ahmadzadeh S; Shekoohi S; Kaye AD
Expert Opin Emerg Drugs; 2023 Dec; 28(4):275-281. PubMed ID: 37909462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
